(Total Views: 335)
Posted On: 04/28/2020 5:47:53 PM
Post# of 36566
Thank you so much! That makes a lot of sense!
The data looks awesome! Hopefully, with this impressive data, things can move quicker than originally expected...
Thanks again!
RJS wrote -
It’s not that AE37 doesn’t work on higher her2 expressing breast cancer patients, it’s that those control patients received Herceptin which is very effective. So DFS didn’t get the p value to show improvement. That was more of a trial design error much discussed in the past. Triple negative patients don’t benefit from Herceptin so we see a clearer comparison to access the vaccine.
Read More: https://investorshangout.com/post/newpost/622...z6KwjXEVjP
The data looks awesome! Hopefully, with this impressive data, things can move quicker than originally expected...
Thanks again!
RJS wrote -
It’s not that AE37 doesn’t work on higher her2 expressing breast cancer patients, it’s that those control patients received Herceptin which is very effective. So DFS didn’t get the p value to show improvement. That was more of a trial design error much discussed in the past. Triple negative patients don’t benefit from Herceptin so we see a clearer comparison to access the vaccine.
Read More: https://investorshangout.com/post/newpost/622...z6KwjXEVjP
(1)
(0)
